Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of cancer.
Astrazeneca has identified anthracycline compounds and antibody-drug conjugates consisting of an antibody covalently bound to anthracycline derivatives reported to be useful for the treatment of cancer.
Merck KGaA has patented substituted bicyclic transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TED interaction inhibitors reported to be useful for the treatment of cancer.
Cogent Biosciences Inc. has described compounds acting as fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of achondroplasia, cancer, craniosynostosis, Alzheimer’s disease, fibrosis, pulmonary fibrosis, systemic scleroderma (systemic sclerosis) and thanatophoric dysplasia, among others.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic diseases.
Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) targeting moiety through a linker reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
Daewoong Pharmaceutical Co. Ltd. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
RSS